Complete elimination in patients who had nowhere left to turn
Em Chicago, pesquisadores apresentaram resultados que reacendem a esperança para pacientes com câncer de cabeça e pescoço avançado — uma das formas mais resistentes da doença. Um medicamento experimental chamado amivantamabe eliminou completamente os tumores de 15 pacientes que haviam esgotado todas as opções convencionais de tratamento, num ensaio clínico com 102 participantes em 11 países. O achado, apresentado na conferência da ASCO, não é uma cura definitiva, mas é um sinal de que a imunoterapia pode abrir caminhos onde a medicina antes encontrava apenas becos sem saída.
- Pacientes com tumores agressivos e recorrentes, resistentes à quimioterapia e à imunoterapia convencional, tinham chegado ao limite do que a medicina podia oferecer — e foi exatamente esse grupo que o ensaio recrutou.
- O amivantamabe agiu por três frentes simultâneas: bloqueou proteínas que alimentam o crescimento tumoral, derrubou as barreiras que escondem o câncer do sistema imunológico e ativou as próprias células de defesa do corpo para atacar os tumores.
- Além das 15 remissões completas, outros 42 participantes viram seus tumores encolher significativamente — e um dos pacientes, o britânico Carl Walsh, recuperou a capacidade de comer e falar normalmente após o tratamento.
- A sobrevida mediana observada foi de cerca de 12 meses, um número que carrega peso real para quem havia ficado sem alternativas clínicas.
- O entusiasmo é temperado pela cautela: estudos maiores ainda são necessários para confirmar eficácia e segurança antes que o medicamento possa ser adotado amplamente no tratamento do câncer de cabeça e pescoço.
No fim de semana passado, durante uma das maiores conferências de oncologia do mundo em Chicago, pesquisadores trouxeram à tona resultados que chamaram a atenção de especialistas: um medicamento experimental chamado amivantamabe havia eliminado completamente os tumores de 15 pacientes com câncer de cabeça e pescoço avançado — pessoas que já não tinham para onde recorrer dentro das opções terapêuticas convencionais.
O ensaio clínico reuniu 102 pacientes em 11 países, todos com tumores agressivos e recorrentes que resistiam à quimioterapia e à imunoterapia padrão. Muitos deles tinham cânceres não associados ao HPV, o que os tornava ainda mais difíceis de tratar. Aplicado por injeção subcutânea a cada três semanas, o amivantamabe produziu resultados além das 15 remissões completas: outros 42 participantes apresentaram redução significativa das lesões. A sobrevida mediana observada foi de aproximadamente 12 meses.
O mecanismo do medicamento é triplo — bloqueia proteínas que estimulam o crescimento do câncer, desfaz as defesas que permitem aos tumores escapar do sistema imunológico e recruta as próprias células de defesa do organismo para combater a doença. Essa combinação parece superar parte da resistência que torna esses cânceres tão difíceis de controlar.
Um dos participantes, o britânico Carl Walsh, tornou-se o rosto humano do ensaio: após o tratamento, recuperou a capacidade de engolir e de falar — funções que o câncer avançado havia comprometido. Recuperar a voz e a mesa não são ganhos abstratos; são a reconquista de uma vida cotidiana.
Os pesquisadores celebram os resultados com cautela. O amivantamabe já é aprovado para alguns tipos de câncer de pulmão e está sendo testado em tumores cerebrais e gástricos. Mas antes de se tornar tratamento padrão para o câncer de cabeça e pescoço, estudos maiores precisarão confirmar sua eficácia e segurança em populações mais amplas. O ensaio é uma peça promissora num esforço global mais amplo para desenvolver imunoterapias capazes de ensinar o sistema imunológico a reconhecer e destruir células tumorais.
At a major cancer research conference in Chicago this past weekend, researchers presented results that caught the attention of oncologists watching for breakthroughs in one of the most stubborn forms of the disease. An experimental immunotherapy drug called amivantamab had completely eliminated tumors in 15 patients with advanced head and neck cancer—patients who had already exhausted the standard treatment options and had nowhere left to turn.
The study involved 102 patients across 11 countries, all of them dealing with aggressive, recurring tumors that had resisted chemotherapy and immunotherapy. What made this group particularly difficult to treat was that many of their cancers were not driven by HPV, the human papillomavirus, which typically responds better to existing therapies. Yet when these patients received amivantamab—delivered as a subcutaneous injection every three weeks—something shifted. Beyond the 15 who saw their tumors disappear entirely, another 42 of the 102 participants experienced significant shrinkage of their lesions. The median survival time observed in the trial was around 12 months, a figure that carries real weight for people who had essentially run out of medical options.
The drug works through what researchers describe as a triple mechanism. It blocks proteins that fuel cancer growth, it disrupts the protective barriers that allow tumors to hide from the immune system, and it activates the body's own defense cells to recognize and attack cancer cells directly. This combination approach appears to overcome some of the resistance that makes head and neck cancers so difficult to treat.
One trial participant, a British man named Carl Walsh, became a visible testament to what the treatment could accomplish. After his tumors shrank, he regained the ability to eat normally and recovered much of his speech—functions that advanced head and neck cancer had stolen from him. These are not abstract improvements. For someone who has lost the capacity to swallow or speak clearly, getting those abilities back is a return to basic human dignity.
The results are being described as encouraging, but researchers are careful about the language they use. The drug is already approved for certain lung cancers and is now being tested against brain, stomach, and other lung tumors. But before amivantamab becomes a standard treatment for head and neck cancer, larger studies will need to confirm both its effectiveness and its safety profile across broader patient populations. The oncology world is in the midst of a global push to develop immunotherapies and personalized cancer vaccines—treatments designed to teach the immune system to recognize and destroy tumor cells. This trial represents one piece of that larger effort, a piece that suggests the approach has real potential, at least for some patients with some forms of cancer.
Notable Quotes
Patient Carl Walsh regained the ability to eat normally and recovered much of his speech after tumors shrank— Trial results presented at ASCO conference
The Hearth Conversation Another angle on the story
Why does it matter that 15 people out of 102 had complete tumor elimination? That's not a majority.
Because these 15 had already failed chemotherapy and immunotherapy. They were out of options. Complete elimination in that population is remarkable—it's not a marginal improvement, it's a second chance.
What does the triple mechanism actually mean in practical terms?
The drug is essentially attacking the cancer from three angles at once. It cuts off the tumor's fuel supply, it removes the invisibility cloak that lets cancer hide from your immune system, and it wakes up your own cells to fight back. It's not just one strategy—it's coordinated.
Carl Walsh regained his ability to eat and speak. Is that typical?
We don't know yet. He's one person in a trial of 102. But it illustrates what's at stake—these aren't just survival numbers. Head and neck cancer takes away fundamental things. Getting them back matters as much as the tumor shrinking.
Why do they need larger studies if the results look this good?
Because 102 patients across 11 countries is still a relatively small sample. You need to know if these results hold up in bigger groups, in different populations, and over longer periods. You also need to understand side effects that might only show up in larger numbers.
Is this drug going to be available soon?
Not for head and neck cancer yet. It's approved for lung cancer already, but for this indication, you're looking at more research first. The pathway exists, but it takes time.